Are low-intensity induction strategies better for older patients with acute myeloid leukemia?
This study compares outcomes of low-intensity versus standard-intensity induction strategies for older patients with acute myeloid leukemia at the Weill Cornell Leukemia Program. From 1999 to 2009, 298 adults ≥ 60 years with AML underwent induction chemotherapy with low-intensity and standard-intensity regimens, based on physician and patient preferences and investigational protocol availability. Overall, 33% of the cohort achieved complete remission with initial treatment, 23% with low-intensity induction and 53% with standard-intensity induction (P<0.0001). The median overall survival was 6.5 months and there was no significant difference in overall survival between patients initially treated with a low-intensity regimen compared to those receiving standard-intensity induction. There were no differences in 30- or 60-day mortality between the two groups.
Leukemia Program, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10065, United States. gar2001@med.cornell.edu
Gail J
GJ
Roboz
Usama
U
Wissa
Ellen K
EK
Ritchie
Usama
U
Gergis
Sebastian
S
Mayer
Joseph M
JM
Scandura
Paul J
PJ
Christos
Eric J
EJ
Feldman
D000368:Aged; D000369:Aged, 80 and over; D000617:Aminoglycosides / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D000079982:Gemtuzumab; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods*; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010087:Oxides / Q000008:administration & dosage; D015363:Quinolones / Q000008:administration & dosage; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome
D000617:Aminoglycosides; D061067:Antibodies, Monoclonal, Humanized; D001152:Arsenicals; D010087:Oxides; D015363:Quinolones; D003561:Cytarabine; D005047:Etoposide; D000079982:Gemtuzumab; C402769:tipifarnib; D000077237:Arsenic Trioxide; D003630:Daunorubicin